Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone therapy in Fukuyama-type congenital muscular dystrophy with FKTN 3 kb insertion
jRCT2031230211Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of prednisolone in Fukuyama congenital muscular dystrophy (FCMD) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Physical examination, Vital signs and 7 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
prednisolone
03
Conditions
Fukuyama congenital muscular dystrophy (FCMD)
Beyond the preview
Go deeper on jRCT2031230211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230211.